Reuters logo
BRIEF-Hemispherx Biopharma updates status of immuno-oncology program in pancreatic cancer
July 10, 2017 / 1:01 PM / 4 months ago

BRIEF-Hemispherx Biopharma updates status of immuno-oncology program in pancreatic cancer

July 10 (Reuters) - Hemispherx Biopharma Inc

* Hemispherx updates status of immuno-oncology program in pancreatic cancer

* Hemispherx Biopharma-‍12 pancreatic patients currently undergoing treatment with single-agent ampligen immuno-oncology therapy in early access program​

* Hemispherx Biopharma-‍ Ampligen appears to be generally well-tolerated by pancreatic patients in program, top line data expected to be reported before year-end​

* Hemispherx Biopharma-laying plans for cancer trials of Ampligen in U.S.; working on plans to expand early access to Ampligen to other european countries Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below